SuperworthDexCom EPS DXCM
Diluted earnings per share by quarter and over the last twelve months, from 2010.
- Last 12 months, to Jun 30, 2026
- $2.52
- Latest quarter, Q2 FY26
- $0.64
- +42% on a year earlier
- Fiscal year 2025
- $2.09
- +47% on the year before
DexCom's earnings per share was $2.52 over the twelve months to Jun 30, 2026, up 76% on a year earlier.
In its latest quarter, Q2 FY26, it was $0.64, up 42% on the same quarter a year before.
Over the five fiscal years to FY2025 it grew 11% a year on average.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | $2.09 | +47% |
| FY2024 | $1.42 | +9% |
| FY2023 | $1.30 | +60% |
| FY2022 | $0.81 | +53% |
| FY2021 | $0.53 | −58% |
| FY2020 | $1.25 | +363% |
| FY2019 | $0.27 | n/a |
| FY2018 | −$0.36 | n/a |
| FY2017 | −$0.15 | n/a |
| FY2016 | −$0.20 | n/a |
| FY2015 | n/a | n/a |
| FY2014 | −$0.08 | n/a |
| FY2013 | −$10000.09 | n/a |
| FY2012 | −$0.20 | n/a |
| FY2011 | −$0.17 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $0.64 | +42% | $2.52 | |
| Q1 FY26 | $0.51 | +89% | $2.33 | |
| Q4 FY25 | $0.67 | +81% | $2.09 | |
| Q3 FY25 | $0.70 | +106% | $1.79 | |
| Q2 FY25 | $0.45 | +29% | $1.43 | |
| Q1 FY25 | $0.27 | −25% | $1.33 | |
| Q4 FY24 | $0.37 | −39% | $1.42 | |
| Q3 FY24 | $0.34 | +17% | $1.66 | |
| Q2 FY24 | $0.35 | +25% | $1.61 | |
| Q1 FY24 | $0.36 | +200% | $1.54 | |
| Q4 FY23 | $0.61 | +177% | $1.30 | |
| Q3 FY23 | $0.29 | +21% | $0.91 |
Against its peers
Companies in Medical - Devices nearest DexCom's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| DXCMDexCom | $2.52 | +76% a year |
| GEHCGE HealthCare Technologies | $4.36 | −11% a year |
| ZBHZimmer Biomet | $4.11 | +0% a year |
| EWEdwards Lifesciences | $1.74 | −75% a year |
| BSXBoston Scientific | $2.47 | +47% a year |
| SYKStryker | $9.65 | +28% a year |
| MDTMedtronic | $4.07 | +12% a year |
| ABTAbbott Laboratories | $2.68 | −66% a year |
| LIVNLivaNova | $3.39 | |
| ITGRInteger | $3.66 | +61% a year |
| Peer median | $3.66 |
Where DexCom ranks
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on DexCom
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.